



Press release

NFL Biosciences strengthens its scientific committee with world-class experts to support the Phase 3 development of NFL-101, its *first-in-class* therapy for tobacco addiction

Montpellier, France, May 12, 2025, 8:30 a.m. CEST – NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALFNL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, today announced the restructuring and strengthening of its Scientific Committee as it plans to advance NFL-101, its smoking cessation therapy, into Phase 3 clinical trial.

NFL-101 stands out with an optimized dosing regimen that promotes patient compliance through only two administrations, a novel mechanism of action, better tolerability than varenicline (Champix®), and increased efficacy in reducing craving, the main factor in relapse.

The committee brings together three internationally recognized experts in addiction and smoking cessation, with extensive experience in clinical trials, along with a leading immunologist, to support the final stages of development.

Prof. Scott E. Lukas, PhD

Prof. Lukas is a Professor of Psychiatry at Harvard Medical School and Director of the McLean Imaging Center and the Behavioral Psychopharmacology Research Laboratory at McLean Hospital (USA). A prominent figure in addiction research, his work has focused extensively on the neurobiology of nicotine dependence, withdrawal, and relapse prevention. A member of NFL Biosciences' Scientific Committee since 2024, Prof. Lukas will continue to provide the company with his support and expertise.

Prof. Bernard Le Foll, MD, PhD

Prof. Le Foll joins NFL Biosciences' Scientific Committee as one of its new members. He is a globally recognized expert in tobacco addiction, serving as a Senior Scientist at the Centre for Addiction and Mental Health (CAMH) and a Professor at the University of Toronto (Canada). His research focuses on the neurobiology of nicotine addiction and the development of pharmacological interventions to help smokers quit.

Prof. Stuart G. Ferguson, PhD

A member of NFL Biosciences' Scientific Committee since 2022, Prof. Ferguson is a Senior Research Fellow at the University of Tasmania's School of Medicine (Australia), specializing in smoking cessation and behavioral interventions for nicotine addiction. His work has contributed significantly to understanding smoking triggers, relapse mechanisms, and effective quitting strategies.

Prof. Eric Tartour, MD, PhD

Prof. Eric Tartour is one of the newest members of NFL Biosciences' Scientific Committee. He is a Professor of Immunology and Head of the Laboratory of Immunology at Hôpital Européen Georges Pompidou in Paris (France). His research focuses on immunology, particularly the role of local immunity, immune

biomarkers for predicting responses to immunotherapy, and the immunomodulatory effects of angiogenesis.

The restructuring of the Scientific Committee underscores NFL Biosciences' commitment to bringing cutting-edge science and clinical expertise to the development of NFL-101. With these distinguished experts on board, the company is poised to advance its breakthrough therapy towards Phase 3 and regulatory approval.

About NFL Biosciences: www.nflbiosciences.com

NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorder.

The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 - ALNFL).

Contacts:

NewCap

Investors relations / Media relations

Mathilde Bohin / Arthur Rouillé

Tel.: +33 (0)1 44 71 94 94

E-mail: nfl@newcap.eu

NFL Biosciences

Bruno Lafont

Tél.: +33 (0)4 11 93 76 67

E-mail: info@nflbiosciences.com